NBIX - Earnings call transcript Q2 2019 | Neurocrine Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Hello, and thank you for joining the Neurocrine Biosciences Reports Second Quarter 2019 Results Call. [Operator Instructions]. It is now my pleasure to turn today's conference over to Kevin Gorman, CEO. Please go ahead.

Kevin Gorman

Thank you very much, and thank you, everyone, for taking the time to join us on our Q2 earnings call. and joined Officer; Gano, Medical Eiry Abernethy, Financial I'm and Chief Officer; call, Commercial Chief Development Chief Business Roberts, Officer; this by our Kyle Strategy Matt Officer. On Benevich, Eric our Chief

Now forward-looking during making statements. this will be we call, all

could please you Jane, our safe So statement. harbor read

Jane Sorensen

could release. subject in concerning afternoon. Investor historical forward-looking be forward-looking is statements company's the update statements including, quarter made today's of these and actual SEC forward-looking XX-Q Any to XXXX and Copies company's conference not Relations company's Kevin? Information we obtained the website. only Form cause are uncertainties. risks to good that differ made in press contained implied date, today Yes, those any statements may call visiting to by this factors page may in and to, statements, filings, disclaim course be the but contained statements on Certain by materially the the that not of results as which are second forward-looking filed are the today's limited from or statements. in obligation

Kevin Gorman

much. has chance at recognize and at press value disorder. teams They've their with and continued here more than got briefly the efforts and our medical Neurocrine. members the trust you TD clearly this family of their patients the commercial to of on prior the I important made release look ability call. care diagnose and professionals, educational efforts a over treating available we increasing I am Thank health to least that just very this everyone to pleased with

a we quarter very see, in sales. can good you had As

the after of for set the year. QX, up of for and that As nicely quarter the half rest said we this quarter us second

Eric a we'll in and your quarter are get to. more and addressing this bit be which going just in Matt to through Now detail questions,

two as as years and growth stronger the being of nevertheless, we increased quarters, seasonality, that INGREZZA but QX persist, there's that quarters seen stressed is of our the that uptake QX always, quarter-to-quarter. expect will we've have but slower being and relatively year-over-year, We and QX launch first QX in with trends and quarter-over-quarter

INGREZZA, since to the We FDA submitted last have into seen conversation, additional go business. good the detail for the our in on, we the quarter which rest will accepted opicapone. our Now very filing progress with -- of and we

for and study, study. We Voyager. II adaptive AADC as design, have is both discussions adult with CAH our program pediatrics, preparing adult on This started the CAH and an program Phase our FDA have with been with collaborative we our

So to each plan. forward of moving and business nicely the quite is aspect

So we do of Matt is questions. what to plenty prepared I'd to remarks to some have over like for your to Eiry so and I'd that for time like get

turn I'll to Matt, it So you. over

Matthew Abernethy

year. opicapone, you, for Thank medicine earnings Good begin, submission second possibly NDA thank this To for Kevin. our team joining the completing next to and I'd XXXX quarter by conference to afternoon, acknowledge you like positioning reapproved our time have for us call.

INGREZZA. In team commercial quarter addition, second strong excellent a an for our did delivering job

million During in of a million quarter XXXX. $XXX.X second the approximately for second XXXX, increased volume the net product INGREZZA sales. scripts, quarter This to XX,XXX scripts, in XX,XXX of prescription $XX.X sales resulting net compares product in

million year-over-year product sales XX% over first were For of to XXXX the million the of half first for $XXX $XXX half XXXX, compared net INGREZZA growth. with

educational initiative. reflect commercial quarter. continued TD Talk number by our awareness second a success provider increase was our patient state About seasonally patient-focused record primarily the improved organization, strong as and rates X,XXX of to driven These During the sequential campaign the refill expanded addition first new disease of and TRx compared results health quarter, the care slower

to during In a inventory QX, TRx. increase in would quarter days benefit channeled in equate to inventory in XXX addition, $X which the million hand increased resulting approximately slight on leading

During to result the Part the to XXXX, script in second quarter primarily donut of XXXX $X,XXX D in net due a of as XXXX, lower QX impact $X,XXX revenue the increased per from Medicare hole. QX

Moving to results of the for second now quarter financial XXXX. our

the During share. $XX.X the quarter, diluted we've recognized million profit or $X.XX of earnings per

associated of net Our noncash of gain investment. includes the Voyager appreciation a income million, $XX with equity Therapeutics' the

of SG&A the XXXX. as Our to the to Voyager collaboration. NDA reflects ongoing the Voyager filing $XX full of related IPR&D expenses a in million R&D FDA's second the were excluding expenses, the R&D compared quarter The QX milestone BIAL operating acceptance and XXXX $XXX.X during opicapone and to related increase million on to quarter impacts the

the quarter second investments, from Regarding cash cash a increase $XX $XXX ended investments, quarter. reflecting million and last in with we and million

our we you As release, XXXX. for saw and in updating range our SG&A guidance R&D earnings are expense

excluding SG&A, expect and of We SG&A to which compares to million $XXX $XXX our guidance $XXX R&D, be previous million R&D this to IPR&D, Ongoing expected range are million to to to million. IPR&D and $XXX $XXX be million. $XXX million, expenses

range offset in to INGREZZA. Our standard PLATINUM discontinue by reflects that T-Force a investment updated decision guidance the expense study slightly

million FDA to AbbVie. to a elagolix, NDA Uterine milestone part for acceptance for moment fibroids, recognize of revenue our take outlook provide collaboration like of will the second $XX of a a as about half agreement I'd event-based XXXX. submission our AbbVie's for comments few revenue we Upon anticipated with

this drug, sequential now hand, a QX to relates believe in the two growth sequential QX do as the of a experience in during that quarters in INGREZZA, and neuropsychiatric awaits QX. it level tier faster of We with we quarters and As seasonality does growth with QX experience specialty slower commercial INGREZZA years believe seasonality year.

new demand by for anticipated For softening. we do impacting quarter, and seasonal an overall increase tempered prescription expect potential incremental inventory TRx continued in patient patient third dynamics growth the and but channel to be volume,

patients. providers Overall, we care make progress very our to continues and remain that the encouraged health by team with

our the I And Roberts. now will Chief to that, Officer, with call Eiry over hand Medical

Eiry Roberts

I hyperplasia and the and Phase health and good on group quarter key on a this Educating congenital peoples' Neurocrine professionals and impact dyskinesia, to everyone lives program. about tardive Matt, here call. our an is efforts medical Thank the provide I'm its Parkinson's at happy to adrenal afternoon on tardive update clinical care disease, for for dyskinesia Biosciences. key focus stakeholders our you,

tardive As of part of study we additional pleased to this share with life the were quality from real-world clinician-confirmed the effort, largest RE-KINECT in data QX, study, screening of possible dyskinesia. patients ongoing

assessments It their was and clinician in involuntary the severity would in including in supports movements, of impact social work patients Also the in that movements. performing and less TD family, not difficulty the of data significant moderate impact reporting moderate patients. life. this a half involuntary of, to potential noteworthy of management of office. the and study in those severe that XX% of diagnosis patients evaluating their almost activities the anxiety health-related RE-KINECT normal in value with assessments involuntary extreme more of the extreme while study of with quality have to or doctor's on well These association and in nearly patient's life to speak with both be depression were patients to very movements tended This the their consistent experienced negative usual symptoms correlated patient-related

May work to states full declare governors proud emotional in across advocacy effects Tardive disorder with on Awareness placed well-being social Dyskinesia I debilitating would first on assets legislators patients. as Week. Mental movement spotlight this Health it week can of and the a and have These important the XX like physical, that also partners, during Month, to order that the highlight and we to of were

the an motor at fluctuations April with and We to will new this Phase tolerability Fee date large once-a-day fluctuations patients efficacy NDA drug studies treatment was The standard huge acceptance clinical submitted program important novel COMT User XX towards two for robust predominantly XX, Drug X,XXX database of FDA the a In opicapone, application month included of the submission disease target this Week NDA action often to opicapone with condition Awareness teams review The the that FDA PDUFA, of of the contained than this a for awareness and broadening Moving assessment April, disease. and Parkinson's inhibitor III forward, given includes or living step has amount be Act, of from Parkinson's earlier subjects with the generated or studies set in More Neurocrine patients exist due NDA were for the TD this XXXX. a extensive BIPARK-I for continue dyskinesia. clinical an tardive XX-month work isolating process Prescription support opicapone. for of received and medicine. we with and development in for NDA of of the motor BIAL, BIPARK-II. in

FDA forward to debilitating agency the we and date. that with across quality hard look the staff our on collaboration thank patients to work U.S. this of am to I this work disorder. in to treatment new for the proud submitted program to the the option bring two like with would dossier the their to I to the and we companies coping of continuing

in the of Turning and to hypoplasia The continues congenital progress adrenal program pharmacodynamics study now pharmacokinetics, adrenal adaptive our and congenital adults II NBI-XXXXX hyperplasia adult tolerability examining in proof-of-concept to Phase with patients pediatric well. patients.

hyperplasia. studies around are generated for study the our patients to of support the congenital from the adrenal discussions data this currently FDA using positive initial NDA-enabling with with adult We design

XX days. our have year, Initial our the for in adapt is will XX We in subjects. of be adaptive NBI-XXXXX also and to initiation proof-of-concept the age. first a younger study administered several also this of in treated, years and -year-olds this that -- XX program to will we the the will pharmacokinetics, nature include pharmacodynamics advanced subjects to XX been II enrolled with patients of study tolerability Later after pediatric study XX Phase examine

of to bring fluctuations QX, Throughout for our program gene ataxia. II Phase to progress program therapy Friedreich's with continued closely Parkinson's disease Voyager forward to a the treatment subsequent targeting and the at we in motor colleagues including VY-AADC programs, work

I give now like our I'd on program. an update to Phase

monoamine of potential Phase to inhibitor range a continue the of the with program discovered transporter-X, our internally neuroscience in clinical We treatment use progress VMATX, disorders. I for vesicular

provide further forward this moves in updates as molecule clinic. will We the

against a we this This In our first research QX, the neurological was novel molecule in development to made evaluation lab under diseases. decision discontinue of in series target. a address also molecule the the to

While the studies, plan And was healthy diseases. we the compound well near the into I to neurological in than this less tolerated it's participants the to target initial backup advance was address in in pharmacokinetic for a lead novel profile clinic molecule therefore, favorable. Phase future

will made remarks. call the am very I I by this pleased clinical our for back the quarter development closing Kevin across hand now progress efforts. to

Kevin Gorman

Matt. Eiry much, and very you, Thank

please? questions, So if Operator, in let's get you now. to could order now, them taking everyone queue your start up

Operator

question first Baird. Brian our take will we from Skorney And Instructions]. [Operator with

Brian Skorney

quarter. Great

we So up saw or increase X,XXX a last of over really mentioned the the terms this in number of you step TRx quarter. quarter big as the

about thinking first kind of the the most is base like it's can spoken terms we versus as over seasonality reauthorization over normal of qualitative of give impacting average the the force color at to new in we're kind this underlying this seeing sort providing be the think patients? what -- somewhere that's you kind look that of you've from in portion Do quarter a in of X,XXX the kind of X,XXX we expansion Or Now the seasonality on from demand any increase increase, before, here think of should now? sales the launch, us And of to headwind we the with is reauthorization but X,XXX what related the of range. you number? increase XQ the if

Matthew Abernethy

this is Matt. hear from to Good So you. Brian,

We a those we good also an through change we did did rates TRx beginning other patients a but the team about what that call, saw exited. quarter perspective. we dynamics last saw not our put existing rate, importantly, in of work record But that is in in that discontinuation how quarter the a we So seasonal headwinds that as per of new importantly, quarter had on patient We the from a see talked and you in payer-related place result at trajectory acknowledged first number refill. what the first we overall of got saw -- we as in the slowdown had reflect a in our of patient quarter. impact

we additions quarter to add? we So within those our lift going really is second factors that anything another this new now that a important quarter there's launch But the us and and going provided flows forward. based seasonal at say record definitely upon of to said, dynamics. those Eric, different quarter. patient would throughout And metric well positions most or we've the in -- that looked us this throughout be ebbs I combined that factors as know to

Eric Benevich

Yes. expanded to I initiative. of well TD just said, awareness last team benefit year some starting to the Matt field Talk in including implemented we're disease what And see and half initiatives sales as other think of piggyback the do unbranded on that year, as our that this of our About the first we

So we of effort QX. that it's and point total of our a the of sort promotional really, I think, jumping-off benefit than effect a more see from so just lower cumulative

Brian Skorney

ask margins Great. COGS, looking being And are seeing on quick a sold? then, real are on Or what just we are previously we INGREZZA here? may expensed If I follow-up could the gross at still product

Matthew Abernethy

gross on margins think good Brian. I is this our of what are INGREZZA, a representation

Operator

with Bank America. Tazeen Our of Ahmad next comes question from

Tazeen Ahmad

think to XX% just of to far. lastly, talk it you stocking you at color to last an quarter Secondly, quarter? thus been saying provided expect call, quarter, would million impact impact to, stayed the that trend then, the have it have or maybe or able even about the build has you $X Matt, rates on be can as I in scrips from has coming you launch? as about relates you changed? on in XX% dispensed of since about stable? say, talked persistence quarter, would well written whether any kind if third not inventory XQ have Or I been Can And Maybe that all the some that continue comment

Matthew Abernethy

saw off the comments what on Yes. Eric close well that in we for a as will inventory persistency from a Tazeen, we perspective with quarter. from the the question. through what distribution access, talk saw as saw then thanks build we the I'll and

Eric Benevich

Yes.

over meaningful course of the dropoff QX terms is of patients that the QX. change in see short persistent didn't any versus answer So we or being

the fill high above So very -- looking percent are what it that's segments. of call also steady. I the been scripts that And very the three written the terms meaning and filled, remains in of ultimately rate, XX% payer still across

patients from about on so coverage good proportion get And really last we've we want with able had you of that payer and Matt, the medication. to that a perspective the feel are part? handle INGREZZA the do to

Matthew Abernethy

Yes.

can a two to inventory, representation overall, increased clean be revenue the stocking in to have on under our think revenue within the basically week also of you what caused quarter, So of to that. see what as if as could some it overall could the relates of bit performance little that was as dynamics. the to our days July hand, still we that there's call different jumping-off quarter. third sell-in make that we're of sure point. perspective, to the a on in read which that But but know, of And a Xth got to underlying in occurs, a coming channel after That the channel recognition you to inventory, we channel network. get end quarter, caused basis, But deal as you felt setting distribution right a It important so but due with see flag out that on then is increase a cause wanted through our for recognized did shift expectations those increase you quarter. could our a you of from we weeks dynamics did overall, we slight slight

Operator

next from Matteis will come Stifel. question Paul Our with

Paul Matteis

fluctuations patient was secondarily, get is I and just consistent last congrats Eiry, wanted you And growth wondering speak are you're quarter expectation registrational my patient? steroid driving on meeting, Matt, Or a sparing then try I what of Is and pretty of path? really the going something endpoint? for seasonality willing that, seasonality? forward more it of your refills And script I saw you'd was to you a Let is speak kind CAH and timing quarter? ahead the to one and average component. the just around to be within a for And you script it at if me underlying if this potential to time FDA to quarter. that's year else? And add per proposing seeing most wondering of

Matthew Abernethy

existing understand what know what Paul. and seasonality and dynamics refill INGREZZA rate thanks, the of the the Yes, business on I question I say quarter. overall more don't patient and seasonality we is, is have impact what for is really the around within each our would pronounced a population does

that patients perspective As TRx bit see quarter, rate. rate vacations our step back then refill being what would normal a steps up a dynamics last the more in we be patient. deem would a QX mentioned QX more we and/or may we in or lowest per be tied refill for up overall rate. to QX QX, from And to back transient. a soften

So that's at how cadence. look we the

patient our dynamics in you TRx harder year-on-year dynamic mature but would look launch likely our QX. growth, we -- poor then QX sequential performance is that's years obviously, we year-on-year still caused tease overall the volatility If these years that's in both As a two you but and There a bit patients. saw as more some on to product, seasonal more in for into seasonality. metrics, see at two how we're out, new only to significant growth, and were

is basically existing meaningful call that per rates I is quarter. new We distributed a a on refill out being within but their impact see do the there, Some would more overall patient in quarter. how of seasonality patients

Eiry Roberts

Paul. Thanks,

data forward a looking that study On submitted very steps we're levels the the to around quarter them the with from in the the package and in and next from androgen with we're the ACTH encouraged that agency see to to be ongoing plans we meaningful this reduction data data that we from CAH released, study. our by POC continue initial the dialogue those very XX-hydroxyprogesterone question, we adult for seeing the We development.

Our to with We the hormone management position the unchanged. points design steroid of in on believe program end disorder. the an registration remained critical and really this levels are fashion patients of ongoing

We for have look around us steroid approach the impact that. CRFX those a we with and the strongly allow significant engaging antagonist without the glucocorticoids to need to also that hormones could super forward physiological owners on FDA believe

as plans on will obviously, development, articulated our of finalize we be the the clinicaltrials.gov. phase and, forward we clinical As moving next study start

Operator

question from Jefferies. Amin come will next with Our Biren

Biren Amin

Can script growth was you much just of prior versus prescribers? by maybe talk How the prescribers about NRx new prescriber? driven

Eric Benevich

Biren, it's Eric.

the as TRXs customers I two and a a would force Matt over way mentioned proportion base. And a we're to for little So launch able is of the describe be think overall was years see driven to prescribers. now. to Certainly, focus be that our of starting that big we're existing we existing reach greater deeper to been it business able that by are repeat in hadn't is NRXs little more our from of we to go expansion seeing as earlier, as and able well trend I prescribing a to coming access with But more individuals the sales previously.

Biren Amin

been Express on rebate? have outreach? the just And you you payer expectations earlier for question then changes conducted I follow-up had Scripts decision this And any Got -- have given it. para-dynamics has year, there sentiment a a on the guess, and any

Eric Benevich

Yes.

a that likelihood the being me hasn't impact doesn't reimbursement really is by priorities patient claim. off had the that securing highest have. what bit -- patient's market we access meaningful have little let in one unusual of we this And or far particular saying a of formulary start on So on is a found for thus off that

in them. the the access meaning we Our to that to right of leave open goal have for is and want patients the to providers choose the their hands choice drug

options. to best the so and choose to therapeutic the think to formulary on for are that the contract And and when patient we position it's allow not trying exclusive plan, they we a we provider, have secure

getting we in started terms of weren't Overall, More launch. dynamics, with the on to haven't the that a the of contacting selectively access have earlier, certainly, to the plan. INGREZZA the going of approved we and we're very patients that, dynamics INGREZZA. we our we being getting seen investment $XX situation So in recently, it with we do being over patients written our And patient's scripts terms in majority by payer with patients we basis doing per been, paying and XX% mentioned an making less we with the payers. pleased think continue benefit. payer in certainly, than to over it with do to for the have we understanding terms filled, access But in carefully. are to And very engage able XX% of when going what I've for that afford likelihood shifts covered monitor of patient like we're any we're prescriptions of where significant selective early month

a it's to favorable to be it. very we in maintain want So and position

Operator

will question from next with Our come Nadeau Cowen. Phil

Philip Nadeau

quarter. on Congratulations the

Just of a questions. couple follow-up

could changes to on be on are people Have either to change Part you've finance impact trying D any Washington, disclosed be D with proposed disclose if figure exposure. curious... the ever the you or what to coverage Would Part done revenue? exposure? willing you proposed would INGREZZA's insurance health Or care. analysis our First In

Matthew Abernethy

Phil, exposure payer Part haven't no, we to is disclosed nor what D. mix our

was our sustainability staying on through the important health as obviously pharma, very associations, the going and and and And far relations industry. affordability, those negotiations, care We're close our an at not and reform, for debate team that's through internal external bio discussion government only the around about but it's Neurocrine. long-term discussions to important. As also trade access

add appropriate our appropriate in through -- at the way. We'll like time in very we voice remain So interested you this. the

Philip Nadeau

it. follow-up just X question mean Matt. I Got

comments and QX was start to ended? highest to some that I Neurocrine want just mentioned number patient during has the how new that seen. aren't you correctly think you heard that prior I remarks, confirm your that on of QX referring your I

Matthew Abernethy

headwinds Eric another a effect we're old cumulative talked record, all We commercial now really initiatives. educational organization, or and the and patients with and And disease getting And this the dyskinesia them getting struggling then, he going about tardive them have as QX the tailwinds. in of seasonal our dynamics expanded launch continues to be diagnosis of ultimately, was one and the help. number awareness is record. INGREZZA TD of to state focus mentioned, aiding campaign QX Yes. on know either

we're patients, our So and help efforts They've incredible for our job and pleased of done was once a with the of QX lot quite us. progress to team. an again another record quarter

Operator

come next question Our with JP will from Anupam Morgan. Rama

Anupam Rama

quarter. just a quick Congrats on one on the Maybe opicapone.

just set, your how With change opicapone? PDUFA activities pre-commercial ongoing now type what upon sales the approval? can us you for are remind infrastructure might of And

Eric Benevich

Anupam, it's Eric.

into we're answer accomplish short I commercial perspective. year, When we last to a the our infrastructure for optimize two adequate goals. reach to disease. One to and sales QX secondly, from dyskinesia launch in make neurology the was we was it opportunity Parkinson's of team that did tardive had opicapone prepare sure INGREZZA, eventual think and expansion for our in to is the with of really that prepared

with of role COMT sales in carbidopa. and for are a market, opicapone, being And campaign that structure levodopa launching to overall disease Parkinson's of prescribers inhibitors of going to really we're remind the treated about unbranded so patients terms the to and later really and in enzyme of this to our well diagnosed COMT year start and with in terms force prepared preparing the we're So commercial then, terms speak, setup. be our

least prior that there's opicapone, consultants opportunity the think launch campaign very that of to an and we well-received contents work certainly, the and that at have the community. of the so our approval done, to in we've been neurology far with And COMT in educational so and elevate importance early

we're looking forward the to really out year. later in So get

Eiry Roberts

will provide opportunity troublesome including reasons a in it some impact from that COMT that a a GI inhibition, space to and motor data the simple build our on-time be to you as once-a-day forward which demonstrated area challenges inhibitors. of I for additional MSL publications hopeful to well with significant on really is just our to group is for saying the is, body of treatment looking opicapone published obviously, this really starting that we're remind just opinion preparing of very Affairs Organization, unmet has mean by And our very this useful is we're motor treatment, would have on medicine with patients. discoloration Medical and neurologists tolerated the already previous some causing of opicapone. in is perspective including and disease that and that with that We've the key without educating ensure from field fluids and still own of dyskinesia that fluctuation. leaders COMT in are release also Parkinson's patients around for working in the mobilized we profile suffer to Also the there doesn't well as patients we significant obviously, of an preparation. the been tolerability seen not other need been with this on fluctuations, and I where better

that the mentally. we opportunity for excited staff and Affairs And the Medical about community this have sure so and our very own we're ready external we're making

Operator

will question Oppenheimer. with Jay next Our Olson from come

Jay Olson

the Congrats quarter. on

quarters trend? put sustainable Or of that is that Now is two could in new record you've together consecutive that mentioned XQ? the patient be a something that starts, seasonality you subject headwinds that to

Matthew Abernethy

Yes.

a I been XX% developing diagnosed of time, as with diagnosed gap We quarters, actually and have this maybe, we've around that market huge between when VMATX. those tardive population. a said at you're and population is in the like and estimate think not prevalent the all dyskinesia as this I previous on mentioned there are

new it state does commercial lifted getting Talk patient awareness perspective, laid out, About patient we've access on to additions disease is definitely patient the from to go and campaign, initiatives going here. have trajectory our drugs. from where expansion, Our a new that focus remain the The but team start TD

to to this and be is a continually expanding quarter-to-quarter continue focus continuing and going -- Our from market perspective. diagnosis

we're So the level how going to at and the that additions. expectations Will on it providers we a two the with on call remain big step have are are continue up for is, quarters. of trajectory? it seen same I we to today the that last patient continue focused frequency describe Our new

Jay Olson

then Great. That's And -- very ahead. helpful. sorry, maybe go

Kevin Gorman

are No. as was in And or one add been thing in I going to able being again, expectations only we've other just real from to through there. the that that QX bit you of conclusions to QX because we're the expansion XXXX. sales little draw as force and know, that was Jay, the only that QX middle statement for going is, right the yet, muddled that through a

to that going dynamics. be dynamic to -- exactly then a the what about see we're so we'll end to to can first think the bit be at seasonal going the better that of kind actually is QX. little of more able I And is prepared talk through, be we'll you this seasonal of So QX kind we

still So we're learning the along way.

Matthew Abernethy

we've as And had. trajectory and out an the the and -- keep patient that grows, the when you funnel fall we more funnel increased pool as before, that need -- on growth have as we add an up organization to the to that talked our more know that other continue aspect of discontinuation we've natural to is base bottom funnel, of

you're this when that thinking and expectations. mindful would remind building we're that So of about you

Jay Olson

deployment on the are Okay. to of I disease to share Based us regards the development? with ask there could on updates and thoughts generating, a Maybe potential you could cash regards capital your of capital balance with and any your question. you're with allocation particularly if flow sheet strength

Kyle Gano

Kyle. question. is Good This

best-in-class first-in-class as we're outset bit we for think, medicines excited well balance a that, which it's of a the mention Neurocrine collaborations, to well provide share I that about of provide cures I important pipeline as potential think our the you of internal here with to at today as our very that as to patients.

goal in release. sure what our have is Neurocrine from Our there's first at and execute earnings we to foremost make here can on you we as first and lot going on see a hand

both strategy a business That part will moving of and preclinical say concert the will said, research our and internal development well in add significant to this now pipeline longer teams no can being continue I as and forward. and continue to work our to as programs be to

Voyager So with up you that to see can that earlier collaboration year. our are we this living

towards collaboration Jnana to XXXX. reported over build projects look We the the had to the also pipeline time. we adding by end of that We on continue

Operator

Our will next come from with question Duncan Fitzgerald. Cantor Charles

Charles Duncan

Lots on top quarter. one questions Congrats Had of asked. INGREZZA on line though. team, the very one and additional beat. nice good Kevin nice

In would terms be bigger guess, role with a new assuming approval of more with the adds? could prescriber base, of I And terms are traction that, the or you in anticipate patient opicapone are that neurologists? enhanced? of you playing And getting neurologists further, psychs

Eric Benevich

it's Charles, Eric.

our neurology psychiatry towards a we're across that line that with about the say from in of directed specialties. in psychiatry results is I neurology. promotional is towards XX% activity remain allocating balance versus two our So call and specialists the perspective would Essentially, effort physician then those

the TD even psychiatry physician. how patient general terms new are In really mind get don't patient neurologists treated of with in the in Patients commonly referred most new a have a Keep undiagnosed any or plays that neurologist primary there's out from adds, area. most by think with been perspective. from care differential patients a that I that growth of that

or -- where neurologist. instances, in a patient So that to refers self

majority promotional I think of mentioned it's from treating NRx with have neurologists So we testament comfortable very are certainly the our effort. acceleration in the and team diagnosis making of TD the say the as I'd majority of our our performance TRx really psychiatry, coming And a certainly, INGREZZA, is high Kevin with but very earlier. conversant the where and of to which is

Charles Duncan

make to question Eiry. sense for quick That me. One

you prepared and designate maybe second Do VMATX not know I focuses duly you when to a a might second mentioned your the it's this end Regarding here, be targeted would able next could just you hear but I the remarks is towards that indication? like to year? candidate inhibition, Or it of this year? and be sense

Eiry Roberts

pleased Phase to Phase continuing this with with and in actually work the I molecule We're progress through we're I.

that identify II given initial our communicating program clinicaltrials.gov we into clinic that. research be to have post us, the candidates on discovery as have important then will Phase to that study, the very we in in efforts might this are We mentioned due And the around obviously, on working a as and, clinical II from available Phase is back for we bring as you as starting well and potentially trial platform going future soon course. we continued

Charles Duncan

but post could sorry of the this year? might mention? is it missed end that possible clinical the were I second or the you Or II that it, be be I'm if trials Phase by year then next in to

Eiry Roberts

that have through timing that you update working as still We're we and openly. we'll

Operator

from David Piper with next Our Jaffray. Amsellem will come question

David Amsellem

Okay.

ones. So two quick

on So business development. first

think we going the the sales leverageable question I you assets, even one as can taking VMATX what, commercial -- force Maybe think understand look commit of guess, you generally, help end could force disorders, or a we a and psychiatric vein, comment is inhibition. fully, focused something large on at market where understand discussion? You more so that sales going think at molecule? you're thinking next Or to of maybe of about mainly extensive, More how it you expanded an assets as the call movement maybe your ready ready have should indication the you or on are now, do about sensibly acquisition about Second us that you on neuro but in asset, on disorders, novel psych? there? more in be not types to you're rare or I think pipeline either being a

Kyle Gano

This is Kyle.

a opportunity think think variables the products, typically think companies. I On of there's think you we asset from couple perspective, public you We overarching of piece, discussed the We business those development types I about about. know talking a are when about that commercial of are some assets. about one market valuable the or those would concerns that of pipeline things not talking today we're the as specificity is in majority that terms see as there own of that vast patent our runway perhaps here the opportunities, we

opicapone, other pieces two of INGREZZA. disrupt we progress might forward. the The launched the products and on needs, a product we about in terms bag moving good And that have in we'll are be that on made worry that

as So that well. also consider we

And then, lastly, M&A if all into optimal product a as type it's a and product tied a to things a for company, opportunity, licensing an thinking think an go about our about licensing. it opportunity, of these as

step where get this is not new ultimately, that perhaps chemical we entities products commercial a bit we down or that the us may years within a looking neurology for to, be I of different but and year offering might are good that think that something, product at couple we -- but next year, what a that's road a be psychiatry. still maybe have pipeline, the

I'll terms VMATX question, that think of I a bit. on So Eiry in touch let your

Eiry Roberts

Thanks for question. the

VMATX the the provide can neurological and broad potential and of a believe inhibition very are to We disorders. committed mechanism VMATX range of in value psychiatric

of in the so them molecules now that as we specific them the to characteristics bring to to examining the want position be including novel we to way molecules forward. have each And decide best clinic, forward one in we and those this target, order take of

I really that's what is say So in at could time. point this

Operator

question next Stanley. Our come Jeff will Hung Morgan from with

Jeff Hung

the on quarter. Congrats

For INGREZZA, script of the couple last than per was net revenue higher quarters.

the trend as net lower So or impact per script D, revenue in And due factors more to other you besides ongoing Part quarter? do specific higher the an there to XQ? Medicare these see were

Eric Benevich

more flag. price from of impact QX Yes, that us, really drug is the would donut to a I first less pronounced we much Part in of result all really the just as of point D and But the donut our reflects the and the hole, really the the impact on having quarter exposure. hole Medicare impact you that's

XXs with just flag hole. deal really, really mix slight the the do mix universe, payer You and donut between within Part extent D but Medicare would some XXs to we the and

Jeff Hung

decision top T-Force then, current the did what And time? line I of the were what talk learn the guess, the hope discontinuation announced? you to since about Okay. GOLD And T-Force can on for would led you to the at PLATINUM, you results

Eiry Roberts

that we we Yes. for taking from PLATINUM. whether a from when the data. announced data consideration distinguish at into negative T-Force in forward of looked not data Tourette's, GOLD be we or could we the path think T-Force data generate those was totality told had the the would valbenazine looking And all at to We that first there I

at decided, was it all and would we front, tolerability whether the determine important were any finding not the data to safety us of us the to challenges in say or basis totality, there be time a but in setback, T-Force forward the any and It's for on in appropriate that of discontinuation all safety PLATINUM on the for take steps or not future. look any

Operator

question from take Goodman our will next Marc SVB we with And Leerink.

Marc Goodman

contracting really this adjust ASPs expect done nets, as kind what about curious, we to have a extent this should time to whether just and first gross contracts. talking down second some is and you've were We the about ASPs I ago. was start come to guys talked of for contracting to you

as just before. range were? the the you change of there? that but it. much dates that you just You It of were $XX-or-so I know roughly quick last big still started TV DTC, be you it, come really get but Can end on into question, to give you down. you all, had of changed? guys seem in is has The on guys a Tourette's, Curious Are want only Voyager to the talk high mentioned going then, million the stopped you study like a thing about we for still the Obviously, when the didn't about that. us you too detail And spending second just numbers. before. And that

Matthew Abernethy

your From and patients tardive dyskinesia. educational DTC understanding to have absolutely very of year overall an process of continue what through front, and this great from expect perspective, accomplishing in we Marc, the the of was that that proud rest just engaging response program, from I'll quick seen are questions. throughout that this

it range. piece as The relates to the second guidance

$XX clinical your I've collaboration. progression other would $XX guidance Voyager and be remains being expectation those that that, that's say where to I would a you programs range. around of And have range. to in a million. band, program, did do assumptions taken some obviously, $XX Our have that that, that you Therapeutics end the investments million initial guidance was be out do our that component taken has within of top Within And and million to the with that previously of given Tourette. that between and range down addition and that one getting mix,

So beyond that, flag I other that. wouldn't on Marc, than anything really

where to know pleased been look this lot over get mentioned, continues of a Eric class relates we've a large we and it contracting. had with We ASPs of at to as But an ensure to time, be. have our engage investment that access grows, the to remains and ultimately we've said -- majority to prescriptions access as written that. as we've patient As great filled date, our we that contracting, as may in before, and

can hit they important most is Our drug. sure the and making ultimately diagnosis aspect

anything to from would So flag there be is nothing we give there be but script lead if thought perspective, per a a contracting material the revenue investment significant in a term time impact if to was we a to perspective. that community it going near material, we were the really from net

Operator

take we And Crédit from Seigerman question last Evan Suisse. our will with

Evan Seigerman

on great Congrats quarter. the

percent these of that mentioned patients Can you average duration off And have patients you of INGREZZA that us number stop is of is fall there what these therapy therapy. patients who natural quantify what for? are the So of taking a and on these the help patients, are? therapy

Eric Benevich

is Eric. This

the cetera. patient other What And with given days we persistency at was drugs perspective exceeded prior said into really since very take: launch. it, quarter-to-quarter. from the haven't launch of numbers we that patients to INGREZZA antipsychotics, the that has have INGREZZA, antidepressants going analog the et seeing what we're typically of were early the is these from looking expectations, an we So our that

data persistency, a year, take over published the medicines at XX% the XX% look that you range their of If the on you'll time. patients see course in to of of

to been rate. recent launch quarter, persistency stated the We of most and days with through, including that better early previously we've has the seen since persistency favorable that the really INGREZZA the up than and have

of the good we drivers one So as feel of growth. about our that

Evan Seigerman

Express anything decision the This you to do then to getting other the States? been contracting. Preferred just kind the INGREZZA from a exclude on call. have Scripts payers Have this with follow-up United been Does feedback National topic on Formulary? has in And from this similar a of

Eric Benevich

commercial it the have us, made the We segment simply of actually think previously volume. not for that less short for Formulary upside So didn't Express represented is We Scripts the the patient the bid Express X% is because on a access. our to Formulary Scripts answer than smaller would for no. we and decision said the patient impact that significant

impact didn't really our on meaningful have so any really strategy. And that

of before, payer access our engage the As their the has and investment future. medication with as make have to it an the is to sure patients have access to said that to access. strategy upside terms think been I because in preferably going we impact for open and Where an that we choose it's we to do

Scripts Express our didn't So or really situation the impact strategy our results.

And engage However, payers meaningful as our gross a said, any begun basis. to limited we there on have with Matt is certainly to impact if disclose on net, we'll that.

Operator

remarks. to for turn And there no over will further Kevin Gorman questions. I final it are

Kevin Gorman

Thank you much. very

in have bit of you the community of a years to psychiatric that been only us, patients we've I address just since lot understand quite we think more at learn. We've the we two begun the and needs to a the INGREZZA learned and have you needs most of large. as these launched following

We will treatment adapting our to to bring be this patients. important constantly efforts

over it's time more it's initiatives adding in and because as that's you've dedicated to. see service and patient's needs, we're to able over call, being So us heard what this you over will education, it's assets,

here partnering Neurocrine exceptional that groups at team that the also We by together and will teams pipeline interim externally science with his work to expand in investing broader continue do our to Kyle and as stuff. and progress and the Neurocrine

and being you continue us And success can investing so. that the do will on finally, we to we've we've that by count And science. disciplined good in had enjoyed

much look to to that, very with talking your and you in thank forward I for upcoming So you I attention meetings.

Operator

today's your participation. does This program. conclude you Thank for

may You disconnect. now

Neurocrine Biosciences (NBIX) 29 Jul 192019 Q2 Earnings call transcript